These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 2358294)

  • 1. Octreotide treatment of acromegaly.
    Wass JA
    Horm Res; 1990; 33 Suppl 1():1-5; discussion 6. PubMed ID: 2358294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of acromegaly with octreotide: effectiveness and tolerability of its pulsatile administration by portable pump.
    Giusti M; Cuttica CM; Cariola G; Valenti S; Sessarego P; Giordano G
    Recenti Prog Med; 1995 May; 86(5):189-94. PubMed ID: 7604174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
    Plöckinger U; Quabbe HJ
    Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly.
    Biermasz NR; Pereira AM; Smit JW; Romijn JA; Roelfsema F
    Growth Horm IGF Res; 2005 Jun; 15(3):200-6. PubMed ID: 15935982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly.
    Ma P; Wang Y; van der Hoek J; Nedelman J; Schran H; Tran LL; Lamberts SW
    Clin Pharmacol Ther; 2005 Jul; 78(1):69-80. PubMed ID: 16003295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
    Laczi F; Magony S; Julesz J
    Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of acromegaly with octreotide, a synthetic analog of somatostatin with extended action].
    Arosio M; Bazzoni N; Faglia G
    Minerva Endocrinol; 1990; 15(1):29-36. PubMed ID: 2274011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical management of acromegaly: effects of SMS 201-995 in 30 patients.
    Pagani G; Montini M; Gianola D; Pagani MD; Tengattini F; Dominoni P; Ghilardi G; Cortesi L; Pedroncelli A; Tonnarelli GP
    Endocrinol Exp; 1990 Mar; 24(1-2):175-85. PubMed ID: 2361459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective multicenter octreotide dose response study in the treatment of acromegaly.
    Ezzat S; Redelmeier DA; Gnehm M; Harris AG
    J Endocrinol Invest; 1995 May; 18(5):364-9. PubMed ID: 7594225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin analogue (SMS 201-995) in resistant acromegaly: a preliminary report.
    Atkinson AB; McKnight JA; McCance DR; Bell PM
    Horm Res; 1990; 33 Suppl 1():7-11; discussion 11-2. PubMed ID: 2358295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Octreotide in the management of active acromegaly due to inoperable growth hormone-secreting adenoma.
    Candrina R
    Recenti Prog Med; 1994 Jan; 85(1):13-9. PubMed ID: 8184174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly.
    Gilbert JA; Miell JP; Chambers SM; McGregor AM; Aylwin SJ
    Clin Endocrinol (Oxf); 2005 Jun; 62(6):742-7. PubMed ID: 15943838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
    Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
    Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
    Turner HE; Thornton-Jones VA; Wass JA
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Experience in treating acromegalic patients with long-acting octreotide].
    Szücs N; Mészáros J; Czirják S; Mondok A; Varga I; Gláz E
    Orv Hetil; 2002 May; 143(19 Suppl):1066-70. PubMed ID: 12063862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical management of acromegaly--what and when?
    Melmed S
    Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():13-7. PubMed ID: 8372605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex.
    van der Lely AJ; Harris AG; Lamberts SW
    Clin Endocrinol (Oxf); 1992 Aug; 37(2):181-5. PubMed ID: 1395069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve 'safe' growth hormone levels.
    Lindsay JR; McConnell EM; Hunter SJ; McCance DR; Sheridan B; Atkinson AB
    Pituitary; 2004; 7(3):139-144. PubMed ID: 16328564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Administration of high-dose octreotide (Sandostatin) by continuous subcutaneous infusion for the treatment of acromegaly.
    White MC; James RA; Chatterjee S; Mother M; Hall K; Dunne MJ; Baister ER; Kendall-Taylor P
    Horm Res; 1990; 33 Suppl 1():13-8; discussion 18-9. PubMed ID: 1972690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment of acromegaly with octreotide (Sandostatin).
    Page MD; Millward ME; Hourihan M; Hall R; Scanlon NF
    Horm Res; 1990; 33 Suppl 1():20-30; discussion 30-1. PubMed ID: 2192978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.